MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
2.130
-0.090
-4.05%
After Hours: 2.234 +0.104 +4.86% 19:37 12/05 EST
OPEN
2.240
PREV CLOSE
2.220
HIGH
2.250
LOW
2.060
VOLUME
131.69K
TURNOVER
--
52 WEEK HIGH
16.94
52 WEEK LOW
1.260
MARKET CAP
56.00M
P/E (TTM)
-0.7617
1D
5D
1M
3M
1Y
5Y
1D
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
Barchart · 2d ago
Weekly Report: what happened at SNTI last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at SNTI last week (1117-1121)?
Weekly Report · 11/24 09:27
Senti Biosciences Price Target Announced at $6.00/Share by Leerink Partners
Dow Jones · 11/21 14:44
Senti Biosciences Initiated at Outperform by Leerink Partners
Dow Jones · 11/21 14:44
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6
Benzinga · 11/21 14:34
Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment
TipRanks · 11/21 13:35
Senti Bio initiated with an Outperform at Leerink
TipRanks · 11/21 13:30
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.